An investigation for investors in NASDAQ:DNAI shares over potential securities laws violations by ProNAi Therapeutics and certain of its directors was announced.
Investors who purchased shares of ProNAi Therapeutics Inc (NASDAQ:DNAI), have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether a series of statements by ProNAi Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Canada based ProNAi Therapeutics, Inc. is a clinical-stage oncology company that is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. On June 6, 2016, ProNAi Therapeutics Inc (NASDAQ:DNAI announced interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). ProNAi Therapeutics Inc’s President and CEO Nick Glover said, “Although [PNT2258] observed modest efficacy …in [the] interim analysis of Wolverine,” the Company has “decided to suspend the development of PNT2258” because the results were not “robust enough to justify continued development of the drug in DLBCL.” Shares of ProNAi Therapeutics Inc (NASDAQ:DNAI) declined from $6.70 per share on June 2, 2016, to $1.86 per share on June 13, 2016.
Those who purchased NASDAQ:DNAI shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego